ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors

In the past year, four antibody–drug conjugates (ADC) were approved, nearly doubling the marketed ADCs in oncology. Among other attributes, successful ADCs optimize targeting antibody, conjugation chemistry, and payload mechanism of action. Here, we describe the development of ABBV-011, a novel SEZ6...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiedemeyer, Wolf R., Gavrilyuk, Julia, Schammel, Alexander, Zhao, Xi, Sarvaiya, Hetal, Pysz, Marybeth, Gu, Christine, You, Monica, Isse, Kumiko, Sullivan, Theodore, French, Dorothy, Lee, Christina, Dang, Angeline T., Zhang, Zhaomei, Aujay, Monette, Bankovich, Alexander J., Vitorino, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381089/
https://www.ncbi.nlm.nih.gov/pubmed/35642431
http://dx.doi.org/10.1158/1535-7163.MCT-21-0851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381089/
https://www.ncbi.nlm.nih.gov/pubmed/35642431
http://dx.doi.org/10.1158/1535-7163.MCT-21-0851

Ejemplares similares